Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00035024.xml
Download PDF
Thromb Haemost 2016; 115(02): 461-463
DOI: 10.1160/th15-05-0376
DOI: 10.1160/th15-05-0376
Letters to the Editor
Resveratrol: beneficial or not? Opposite effects of resveratrol on hypoxia-dependent PAI-1 expression in tumour and primary cells
Financial support: This work was supported by grants from Wilhelm Sander Foundation (Grant 2008 .043.1) to ED, Biocenter Oulu, Sigrid Juselius Foundation, and Finnish Academy of Sciences to TK.
Further Information
Publication History
Received:
05 May 2015
Accepted after major revision:
14 July 2015
Publication Date:
22 November 2017 (online)
-
References
- 1 Delias C, Loskutoff DJ. Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease. Thromb Haemost 2005; 93: 631-640.
- 2 Cesari M, Pahor M, Incalzi RA. Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibri-nolysis and age-related subclinical and clinical conditions. Cardiovasc Ther 2010; 28: e72-91.
- 3 Ghosh AK, Vaughan DE. PAI-1 in tissue fibrosis. J Cell Physiol 2012; 227: 493-507.
- 4 Duffy MJ. Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers in breast cancer: from pilot to level 1 evidence studies. Clin Chem 2002; 48: 1194-1197.
- 5 Duffy MJ, Crown J. A personalized approach to cancer treatment: how biomarkers can help. Clin Chem 2008; 54: 1770-1779.
- 6 Dimova EY, Kietzmann T. Metabolic, hormonal and environmental regulation of plasminogen activator inhibitor-1 (PAI-1) expression: lessons from the liver. Thromb Haemost 2008; 100: 992-1006.
- 7 Renaud S, de Lorgeril M. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet 1992; 339: 1523-1526.
- 8 Hsieh TC, Wu JM. Resveratrol: Biological and pharmaceutical properties as anticancer molecule. Biofactors 2010; 36: 360-369.
- 9 Baur JA, Ungvari Z, Minor RK. et al. Are sirtuins viable targets for improving healthspan and lifespan?. Nat Rev Drug Discov 2012; 11: 443-461.
- 10 Carter LG, D’Orazio JA, Pearson KJ. Resveratrol and cancer: focus on in vivo evidence. Endocr Relat Cancer 2014; 21: R209-225.
- 11 Pervaiz S, Holme AL. Resveratrol: its biologic targets and functional activity. Antioxid Redox Signal 2009; 11: 2851-2897.
- 12 Binder BR, Christ G, Gruber F. et al. Plasminogen activator inhibitor 1: physiological and patho-physiological roles. News Pysiol Sci 2002; 17: 56-61.
- 13 Kietzmann T, Roth U, Jungermann K. Induction of the plasminogen activator inhibitor-1 gene expression by mild hypoxia via a hypoxia response element binding the hypoxia inducible factor-1 in rat hepatocytes. Blood 1999; 94: 4177-4185.
- 14 Dimova EY, Moller U, Herzig S. et al. Transcrip-tional regulation of plasminogen activator in-hibitor-1 expression by insulin-like growth factor-1 via MAP kinases and hypoxia-inducible fac-tor-1 in HepG2 cells. Thromb Haemost 2005; 93: 1176-1184.
- 15 Kortlever RM, Higgins PJ, Bernards R. Plasmi-nogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence. Nat Cell Biol 2006; 08: 877-884.
- 16 Shetty S, Shetty P, Idell S. et al. Regulation of plas-minogen activator inhibitor-1 expression by tumor suppressor protein p53. J Biol Chem 2008; 283: 19570-19580.
- 17 Samoylenko A, Roth U, Jungermann K. et al. The upstream stimulatory factor-2a inhibits plasmi-nogen activator inhibitor-1 gene expression by binding to a promoter element adjacent to the hy-poxia-inducible factor-1 binding site. Blood 2001; 97: 2657-2666.
- 18 Dimova EY, Kietzmann T. Cell type-dependent regulation of the hypoxia-responsive plasminogen activator inhibitor-1 gene by upstream stimulatory factor-2. J Biol Chem 2006; 281: 2999-3005.
- 19 Fukui M, Yamabe N, Kang KS. et al. Growth-stimulatory effect of resveratrol in human cancer cells. Mol Carcinog 2010; 49: 750-759.
- 20 Brakenhielm E, Cao R, Cao Y. Suppression of an-giogenesis, tumor growth, and wound healing by resveratrol, a natural compound in red wine and grapes. FASEB J 2001; 15: 1798-1800.
- 21 Rosenow A, Noben JP, Jocken J. et al. Resveratrol-induced changes of the human adipocyte secretion profile. J Proteome Res 2012; 11: 4733-4743.
- 22 Zagotta I, Dimova EY, Funcke JB. et al. Resveratrol suppresses PAI-1 gene expression in a human in vitro model of inflamed adipose tissue. Oxid Med Cell Longev 2013; 2013: 793525.
- 23 Ahn J, Lee H, Kim S. et al. Resveratrol inhibits TNF-alpha-induced changes of adipokines in 3T3-L1 adipocytes. Biochem Biophys Res Com-mun 2007; 364: 972-977.
- 24 Yen GC, Chen YC, Chang WT. et al. Effects of polyphenolic compounds on tumor necrosis factor-alpha (TNF-alpha)-induced changes of adipo-kines and oxidative stress in 3T3-L1 adipocytes. J Agric Food Chem 2011; 59: 546-551.
- 25 Olholm J, Paulsen SK, Cullberg KB. et al. Anti-inflammatory effect of resveratrol on adipokine expression and secretion in human adipose tissue ex-plants. Int J Obes 2010; 34: 1546-1553.
- 26 Xu F, Wang Y, Cui W. et al. Resveratrol Prevention of Diabetic Nephropathy Is Associated with the Suppression of Renal Inflammation and Mesangial Cell Proliferation: Possible Roles of Akt/NF-kap-paB Pathway. Int J Endocrinol 2014; 2014: 289327.
- 27 Suenaga F, Hatsushika K, Takano S. et al. A possible link between resveratrol and TGF-beta: resver-atrol induction of TGF-beta expression and signaling. FEBS Lett 2008; 582: 586-590.